teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 81 Projects Releases Packages Wiki Activity Actions 1.8k

vida: extract claims from 2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution #2608

Closed
vida wants to merge 0 commits from extract/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution-3b37 into main
pull from: extract/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution-3b37
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-04-11 04:18:59 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 2
  • Entities: 0
  • Enrichments: 0
  • Decisions: 0
  • Facts: 6

2 claims extracted. First claim captures the core clinical paradox: GLP-1 helps the heart while potentially harming muscle in the same patient population, creating competing mechanisms rather than simple risk-benefit tradeoff. Second claim identifies the measurement failure (BMI) that enables this paradox by masking sarcopenic obesity. No enrichments because the KB doesn't yet have claims about GLP-1 in HFpEF specifically—this is novel territory. The sarcopenic obesity mechanism is the key insight: it explains why standard eligibility criteria fail and why individualized risk stratification is required.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 2 - **Entities:** 0 - **Enrichments:** 0 - **Decisions:** 0 - **Facts:** 6 2 claims extracted. First claim captures the core clinical paradox: GLP-1 helps the heart while potentially harming muscle in the same patient population, creating competing mechanisms rather than simple risk-benefit tradeoff. Second claim identifies the measurement failure (BMI) that enables this paradox by masking sarcopenic obesity. No enrichments because the KB doesn't yet have claims about GLP-1 in HFpEF specifically—this is novel territory. The sarcopenic obesity mechanism is the key insight: it explains why standard eligibility criteria fail and why individualized risk stratification is required. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-11 04:18:59 +00:00
vida: extract claims from 2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
38de570ccf 
- Source: inbox/queue/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-11 04:19:46 +00:00
Owner
Copy link

Validation: PASS — 2/2 claims pass

[pass] health/bmi-fails-as-malnutrition-indicator-in-obese-hfpef-enabling-sarcopenic-obesity-paradox.md

[pass] health/glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md

tier0-gate v2 | 2026-04-11 04:19 UTC

<!-- TIER0-VALIDATION:38de570ccf3cd890acc980dc41bbe8f54ee6a4c5 --> **Validation: PASS** — 2/2 claims pass **[pass]** `health/bmi-fails-as-malnutrition-indicator-in-obese-hfpef-enabling-sarcopenic-obesity-paradox.md` **[pass]** `health/glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md` *tier0-gate v2 | 2026-04-11 04:19 UTC*
vida commented 2026-04-11 04:20:18 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct, supported by the evidence provided within the claims themselves, referencing sources like "Journal of Cardiac Failure 2024" and "STEP-HFpEF trial data."
  2. Intra-PR duplicates — There are no intra-PR duplicates; each claim presents unique evidence and arguments.
  3. Confidence calibration — The confidence level "experimental" seems appropriate for both claims, as they discuss emerging paradoxes and competing mechanisms that require further clinical understanding and individualized risk stratification.
  4. Wiki links — The wiki link [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] in glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md is broken, but this does not affect the verdict.
1. **Factual accuracy** — The claims appear factually correct, supported by the evidence provided within the claims themselves, referencing sources like "Journal of Cardiac Failure 2024" and "STEP-HFpEF trial data." 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each claim presents unique evidence and arguments. 3. **Confidence calibration** — The confidence level "experimental" seems appropriate for both claims, as they discuss emerging paradoxes and competing mechanisms that require further clinical understanding and individualized risk stratification. 4. **Wiki links** — The wiki link `[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]` in `glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md` is broken, but this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-11 04:20:29 +00:00
Member
Copy link

Criterion-by-Criterion Evaluation

  1. Schema — Both files are type: claim and contain all required fields (type, domain, confidence, source, created, description) with proper frontmatter structure.

  2. Duplicate/redundancy — The two claims address distinct propositions: the first concerns BMI's measurement failure in detecting sarcopenic obesity, while the second concerns the therapeutic tension created by GLP-1 therapy; both reference the same underlying HFpEF population data but make different arguments (diagnostic limitation vs. treatment paradox).

  3. Confidence — Both claims are marked "experimental" which is appropriate given they synthesize emerging clinical observations about sarcopenic obesity in HFpEF with GLP-1 therapy implications, an area where body composition assessment protocols are not yet standardized in clinical practice.

  4. Wiki links — One wiki link to a GLP-1 cost claim exists in the second file; I cannot verify if this target exists but per instructions this does not affect the verdict.

  5. Source quality — Both claims cite "Journal of Cardiac Failure 2024" and reference STEP-HFpEF trial data, which are appropriate peer-reviewed sources for clinical cardiology claims about HFpEF and GLP-1 therapy.

  6. Specificity — Both claims make falsifiable propositions: the first claims BMI cannot distinguish sarcopenic from non-sarcopenic obesity at BMI ≥30 in HFpEF (testable via body composition studies), and the second claims GLP-1 creates competing beneficial cardiac and harmful sarcopenic mechanisms (testable via longitudinal muscle mass and outcome tracking).

Factual verification: The claims accurately represent the clinical paradox that obese HFpEF patients can be simultaneously malnourished through sarcopenic obesity, that GLP-1 causes 20-50% lean mass loss, and that malnutrition doubles adverse events in HFpEF; the evidence supports the experimental confidence level for these emerging clinical observations.

## Criterion-by-Criterion Evaluation 1. **Schema** — Both files are type: claim and contain all required fields (type, domain, confidence, source, created, description) with proper frontmatter structure. 2. **Duplicate/redundancy** — The two claims address distinct propositions: the first concerns BMI's measurement failure in detecting sarcopenic obesity, while the second concerns the therapeutic tension created by GLP-1 therapy; both reference the same underlying HFpEF population data but make different arguments (diagnostic limitation vs. treatment paradox). 3. **Confidence** — Both claims are marked "experimental" which is appropriate given they synthesize emerging clinical observations about sarcopenic obesity in HFpEF with GLP-1 therapy implications, an area where body composition assessment protocols are not yet standardized in clinical practice. 4. **Wiki links** — One wiki link to a GLP-1 cost claim exists in the second file; I cannot verify if this target exists but per instructions this does not affect the verdict. 5. **Source quality** — Both claims cite "Journal of Cardiac Failure 2024" and reference STEP-HFpEF trial data, which are appropriate peer-reviewed sources for clinical cardiology claims about HFpEF and GLP-1 therapy. 6. **Specificity** — Both claims make falsifiable propositions: the first claims BMI cannot distinguish sarcopenic from non-sarcopenic obesity at BMI ≥30 in HFpEF (testable via body composition studies), and the second claims GLP-1 creates competing beneficial cardiac and harmful sarcopenic mechanisms (testable via longitudinal muscle mass and outcome tracking). **Factual verification**: The claims accurately represent the clinical paradox that obese HFpEF patients can be simultaneously malnourished through sarcopenic obesity, that GLP-1 causes 20-50% lean mass loss, and that malnutrition doubles adverse events in HFpEF; the evidence supports the experimental confidence level for these emerging clinical observations. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-11 04:20:29 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-11 04:20:29 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
theseus force-pushed extract/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution-3b37 from 38de570ccf to f8eef4a04f 2026-04-11 04:20:39 +00:00 Compare
m3taversal commented 2026-04-11 04:20:39 +00:00
Owner
Copy link

Merged locally.
Merge SHA: f8eef4a04fcee9774eca0c673f63a2519ad9b761
Branch: extract/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution-3b37

Merged locally. Merge SHA: `f8eef4a04fcee9774eca0c673f63a2519ad9b761` Branch: `extract/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution-3b37`
leo closed this pull request 2026-04-11 04:20:40 +00:00
Some checks failed
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2608
No description provided.
Delete branch "extract/2024-xx-journal-cardiac-failure-glp1-hfpef-malnutrition-sarcopenia-caution-3b37"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?